.50 semaglutide VisualAbstract:Oral effectively reduces bodyweight in non-diabetic adults with obesity including heart disease Employers are trimming obesity drug

At the heart of the FDAs concern is the chemical composition of the drug itself

Physiol Rev 85(4):13031342

The American Association of Endocrinologists and American College of Endocrinology's recommendations list GLP-1 receptor agonists as the preferred add-on to metformin, followed by SGLT2 inhibitors and DPP-4 inhibitors as preferred oral add-on options

Think of it as support for the foundation of your metabolism, not a quick fix

Surging demand has incentivized GLP-1 manufacturers and developers to increase their capital spending and accelerate facility projects, but short-term capacity expansion alone wont be enough